Updated:
Biosynex
Biosynex, founded by Larry Abensur, is a French diagnostics acquirer and point-of-care specialist that scaled rapidly during the COVID-19 pandemic.
Biosynex
Founded in 2005 by Larry Abensur, Biosynex operates from Illkirch-Graffenstaden near Strasbourg, where it evolved from distributing rapid diagnostic tests into a developer and acquirer of point-of-care technologies. The company went public on Euronext Growth Paris, raising capital to consolidate a fragmented diagnostics market across France and neighboring European countries. Abensur remains the controlling shareholder and CEO, steering a firm whose revenue profile has been defined by sudden, lumpy surges rather than steady-state growth. Biosynex's portfolio spans infectious disease testing, women's health diagnostics, and point-of-care devices for professional and home use. The group owns several subsidiary brands, including nadal-test for lateral-flow assays and the developmental-stage Biogroup device platform for near-patient testing. During the COVID-19 pandemic, Biosynex became a primary French supplier of antigen and antibody tests, generating over €400 million in revenue during peak quarters. Post-pandemic, the firm shifted to capital allocation, acquiring Swiss diagnostics firm Riva and maintaining a strategic equity stake in listed diagnostics peer Theradiag. Deployment covers France, Switzerland, Belgium, and select African markets through distributor networks. Headquarters remain in Alsace, with additional operational sites tied to recent acquisitions in Switzerland. The firm's professional headcount and board composition are not publicly detailed beyond Abensur's executive leadership and a small scientific advisory panel. Biosynex has not disclosed participation in family-office-style co-investment clubs or philanthropic vehicles. In November 2024, Biosynex announced the strategic acquisition of Riva Group, a Swiss diagnostics manufacturer, expanding its product line and European distribution capabilities (per the firm's official disclosure, November 2024). Biosynex's structural differentiator is its post-COVID treasury model. Rather than returning windfall cash to shareholders or diversifying into unrelated sectors, Abensur has doubled down on a buy-and-integrate strategy within European diagnostics — effectively running a concentrated, publicly listed holding company for point-of-care assets. This hybrid between an operating company and an acquisition vehicle is uncommon among French small-cap life-science firms, most of which remain single-product focused or sell to larger strategics after their first clinical win.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Illkirch-Graffenstaden
Corporate office
Illkirch-Graffenstaden, France
Principals
Larry Abensur
Founder and CEO
Sector focus
Frequently asked questions
Who runs investment and acquisition decisions at Biosynex?
Larry Abensur, the founder and CEO, controls strategic and capital allocation decisions. As the dominant shareholder, he operates without an external investment committee, personally driving the acquisition pipeline and integration strategy. The 2024 purchase of Swiss firm Riva Group was executed under his direct oversight.
How does Biosynex source acquisition targets?
Abensur leverages a long tenure in European diagnostics distribution to identify targets through direct industry relationships rather than through formal auction processes. The firm focuses on small-to-midsize point-of-care and infectious-disease testing companies in France, Switzerland, and neighboring markets that can be consolidated under the Biosynex umbrella.
Is Biosynex structured as a family office or an operating company?
Biosynex is a publicly traded operating company on Euronext Growth Paris, not a family office. However, its post-COVID posture — accumulating cash from testing windfalls and redeploying it into serial acquisitions — resembles a concentrated holding vehicle more than a traditional diagnostics manufacturer.
What happened to Biosynex's revenue after the COVID-19 testing boom?
Quarterly revenue peaked above €200 million during the pandemic's highest testing demand, then normalized sharply as government testing programs wound down. Biosynex has since used retained earnings to fund acquisitions like Riva Group rather than pursuing rapid revenue replacement.
Which geographic markets does Biosynex serve?
France remains its primary market. The 2024 Riva Group acquisition added direct Swiss and Belgian distribution, and the firm maintains an export channel into Francophone Africa and parts of the Middle East through third-party distributors.
Does Biosynex maintain any separate philanthropic or investment vehicles?
There is no public record of a separate foundation, family office vehicle, or co-investment structure tied to Larry Abensur or Biosynex. The company channels capital deployment exclusively through direct acquisitions and internal R&D.
What investment stages does Biosynex typically target?
Biosynex targets commercial-stage diagnostics companies with existing revenue and regulatory approvals, not early-stage biotech. The Riva Group acquisition exemplifies this strategy — a fully operational Swiss manufacturer with an established product catalog and European market access.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: